Neuronetics, Inc. (STIM) Positions as Neurohealth Leader with Adolescent Breakthrough

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Neuronetics, Inc. is placed sixth among them.

Neuronetics, Inc. (NASDAQ:STIM) is a commercial-stage medical technology company specializing in neurohealth solutions, including its flagship NeuroStar Advanced Therapy System, a leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder and obsessive-compulsive disorder. The company integrates technology development with direct patient care through Greenbrook TMS centers and the Better Me Provider program, combining innovation with accessibility.

In Q2 2025, Neuronetics, Inc. (NASDAQ:STIM) reported $38.1 million in revenue, marking a 132% year-over-year increase, driven by Greenbrook integration and expansion to 95 clinics across 15 states. The Better Me Program has accelerated patient access, while the company is expanding its SPRAVATO (esketamine) program to complement TMS therapy in treating resistant depression. Revenue for fiscal 2025 is projected between $149 million and $155 million, with positive cash flow from operations anticipated by Q4 2025.

The business continues investing in growth and talent, including inducement awards for new employees, while navigating ongoing challenges in profitability and stock volatility. The company recently gained FDA clearance for NeuroStar in adolescents, establishing it as a first-line therapy without prior medication failure and highlighting its innovative market position.

Investor engagement remains a priority, with recent presentations at the August 2025 Canaccord Genuity Growth Conference outlining strategic expansion, clinical progress, and market opportunities. By combining advanced TMS technology with a broad treatment network and ongoing program expansion, Neuronetics, Inc. (NASDAQ:STIM) positions itself as a distinctive player in the evolving neurohealth sector, targeting both adult and adolescent populations while driving adoption of non-pharmacologic therapies.

While we acknowledge the potential of STIM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.